Clinical Trial Update: Inhaled Amikacin Solution BAY41-6551 as Adjunctive Therapy in the Treatment of Gram-Negative Pneumonia [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating inhaled amikacin solution BAY41-6551 as adjunctive therapy for Gram-negative pneumonia has completed and results were posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumonia

Drugs mentioned

• Amikacin inhalation solution BAY41-6551 (amikacin)

Snippet

Sponsor: Bayer | Conditions: Pneumonia, Bacterial | Phase 3 | Status: COMPLETED | Results posted: 2018-06-26